Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 10, 2009

Fovea Gains EU Marketing Rights for Dyax’ Candidate in Ophthalmic Uses

  • Fovea obtained a license to develop and commercialize Dyax’ compound DX-88 in retinal diseases. The agreement gives Fovea marketing rights in the EU, while Dyax retains marketing rights for all other territories. If commercialized, each company will pay the other a tiered royalty on net sales in their respective territories.

    Fovea will fund development of DX-88 for the treatment of RVO-induced macular edema (retinal vein occlusion) for approval in worldwide markets. For all other ophthalmic uses of DX-88, Fovea will be responsible for development to meet EU regulatory requirements and Dyax will take care of any additional requirements needed to obtain approval outside the EU.

    “As a potent plasma kallikrein inhibitor, DX-88 has the potential to be a breakthrough therapy in reducing macular edema, a leading cause of visual loss in multiple ophthalmic diseases,” explains Bernard Gilly, president and CEO of Fovea.

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »